Nexigen GmbH Appoints Dr. Jorg Vollmer as CEO
Between 2008 and 2011 Dr. Vollmer was Managing Director of Coley Pharmaceutical GmbH, a subsidiary of Pfizer Inc. Coley Pharmaceutical was then part of Pfizer Research. As part of Pfizer's Oligonucleotide Therapeutics Unit (OTU), Dr. Vollmer concentrated on the development of gene-silencing nucleic acid therapeutics such as siRNA and antisense. This field perfectly matches Nexigen's positioning as a developer of innovative drugs targeting previously inaccessible disease mechanisms.
Before 2008, Dr. Vollmer held several senior management positions at Coley Pharmaceutical Group, latest as Vice President Discovery & Development. In this role he was responsible for the identification and evaluation of novel product candidates and new research and application areas. Coley Pharmaceutical was a pioneer in developing a class of drug candidates called TLR Therapeutics, oligonucleotide drugs to modulate the immune system. Jörg Vollmer holds a degree in Biology from the University of Freiburg and a PhD in Immunology from the Max-Planck-Institute of Immunobiology.
Dr. Vollmer is Member of the Board of the biotechnology network BioRiver e.V. in North Rhine-Westphalia.
"With his broad experience in discovery & development and from the pharmaceutical industry, Dr. Vollmer is the ideal candidate for this key position within our company", said Dr. Hanjo Hennemann, CSO and founder of Nexigen.
"Nexigen's proprietary peptide platform has the potential to enable successful development of peptide modulators targeting disease mechanisms which traditionally have not been accessible for drug discovery. I am excited to work with Hanjo Hennemann and his team and to contribute to the future success of Nexigen", comments Dr. Jörg Vollmer.
The appointment of Dr. Vollmer as CEO of Nexigen strengthens the company in its process of becoming one of the leading drug developers for innovative therapeutics with novel and potentially superior properties.
About Nexigen GmbH
Nexigen GmbH was founded in August 2007, obtained its first capital in 2008 und develops peptide therapeutics with novel modes of action for the treatment of cancer. The company aims at so far inaccessible proteins, which are crucially involved in the onset and progression of tumors. Nexigen relies on proprietary and innovative peptide screening technologies in living cells. This allows for the time and cost-efficient access to drug discovery. Currently Nexigen GmbH cooperates with various biotech companies and successfully completed projects with leading pharmaceutical companies
Please contact us for further information!
Daniela Thiebes
Nexigen GmbH
+49 (221) 33 77 72-00
thiebes@nexigen.de